News

Elicio Therapeutics, a next generation immuno-oncology company, announced that it has closed its $33 million Series B financing. Proceeds from the financing will be used to advance…
Read More...

Lantheus Holdings, Inc., parent company of Lantheus Medical Imaging, Inc., a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and…
Read More...

Cellular Biomedicine Group, a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced it…
Read More...

GlaxoSmithKline plc (GSK) and Innoviva, Inc. (INVA) announced the filing of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) seeking an additional…
Read More...

Xylyx Bio announced the development of substrates for anti-fibrotic drug discovery as the next stage of its pipeline of pre-clinical cell culture products. Through the development of…
Read More...

Thermo Fisher Scientific announced the expansion of its API manufacturing capabilities following the completion of its previously announced acquisition of an active pharmaceutical…
Read More...

Astellas Pharma Inc. announced that it will invest nearly $13 million into two innovation incubators operated by LabCentral, a premier United States-based laboratory facility for…
Read More...

Elligo Health Research, a healthcare-enabling research organization, has received a grant from the U.S. Food and Drug Administration (FDA) for a follow-on project to extend the value of…
Read More...

Cellectis and Lonza announced that the companies have entered into a manufacturing service agreement covering clinical manufacturing of Cellectis’ allogeneic UCART product candidates…
Read More...

Novartis announced an important step in reimagining medicine by founding the Novartis AI innovation lab and by selecting Microsoft Corp. as its strategic AI and data-science partner for…
Read More...

Servier announced the acquisition of PIXUVRI from CTI BioPharma. PIXUVRI is a treatment for adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma.…
Read More...

Chimerix announces an exclusive global license agreement with SymBio Pharmaceuticals, Ltd (SymBio), under which SymBio has exclusively licensed the worldwide rights to develop,…
Read More...

Ocugen, Inc. a clinical stage biopharmaceutical company focused on innovative therapies that address rare and underserved eye diseases, has entered into a strategic partnership with…
Read More...

Moberg Pharma AB has signed an exclusive license agreement with Taisho Pharmaceutical Co., Ltd for development, registration and commercialization of MOB-015 in Japan. Under the…
Read More...

Swedish Orphan Biovitrum AB (publ) (Sobi) announced a definitive agreement to acquire Dova Pharmaceuticals, Inc. by means of a tender offer. The consideration consists of an upfront…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) has approved Rituxan (rituximab), in combination with glucocorticoids, for the treatment of granulomatosis with…
Read More...

Currax Pharmaceuticals LLC, a specialty biopharmaceutical company with both Branded and generic business units, announced the acquisition of Nalpropion Pharmaceuticals. As a result of…
Read More...

Clover Biopharmaceuticals announced that the first patient was dosed in another Phase I trial of SCB-313, an investigational fully-human TRAIL-Trimer fusion protein, in China for the…
Read More...

Kinoxis Therapeutics Pty Ltd, a pre-clinical stage biotechnology company developing novel therapies for substance use disorders and other central nervous system disorders, has been…
Read More...

Moderna, Inc., a clinical-stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients,…
Read More...